key: cord-0913249-iaz57bpa
authors: Bouayad, Abdellatif
title: Features of HLA class I expression and its clinical relevance in SARS‐CoV‐2: What do we know so far?
date: 2021-04-01
journal: Rev Med Virol
DOI: 10.1002/rmv.2236
sha: 36d3155e8ac12ebd7362d7adc003b5036fcbe179
doc_id: 913249
cord_uid: iaz57bpa

Modifications in HLA‐I expression are found in many viral diseases. They represent one of the immune evasion strategies most widely used by viruses to block antigen presentation and NK cell response, and SARS‐CoV‐2 is no exception. These alterations result from a combination of virus‐specific factors, genetically encoded mechanisms, and the status of host defences and range from loss or upregulation of HLA‐I molecules to selective increases of HLA‐I alleles. In this review, I will first analyse characteristic features of altered HLA‐I expression found in SARS‐CoV‐2. I will then discuss the potential factors underlying these defects, focussing on HLA‐E and class‐I‐related (like) molecules and their receptors, the most documented HLA‐I alterations. I will also draw attention to potential differences between cells transfected to express viral proteins and those presented as part of authentic infection. Consideration of these factors and others affecting HLA‐I expression may provide us with improved possibilities for research into cellular immunity against viral variants.

CTLs are just beginning to be understood. The significance of the interaction between HLA-I molecules and their receptors depends on the HLA-I cell surface expression state or HLA genotype of the individuals. Thus, aberrant or reduced expression of these molecules might be clinically relevant since, in exposed patients, including older 10, 11 and adults with comorbidities (cancer, male sex), 12,13 they could escape from CTL and NK cell killing, 14 eventually leading to viral persistence 15, 16 and subsequent severity of Covid-19.

This review will analyse characteristic features of altered HLA-I expression found in SARS-CoV-2, focussing on the most documented HLA-I alterations.

SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE2) and type 2 transmembrane serine protease (TMPRSS2) to bind and enter into target cells such as alveolar epithelial cells. 17, 18 During the time preceding stimulation of T-and B-cell responses, innate immunity is mediated by interferon (IFN) α/β, which prevents infection, and NK cells, which eliminate infected cells. NK cells control viral replication and spreading by spontaneous cytolysis or by secreting cytokines such as IFN-γ and chemokines. 19 HLA-E can present self-signal peptides derived from other HLA molecules (HLA-A, -B, -C and -G) 20 to NK cells through direct interaction with NKG2/CD94 complex (NKG2A or NKG2C), 21 a C-type lectin receptor expressed mainly on NK lymphocytes. It interacts with inhibitory NKG2A with higher affinities than activating NKG2C. 22 Once SARS-CoV-2 has evaded innate immunity, 23 viral control relies on cellular and humoral adaptive immunity. Naïve CD8+ T cells are activated to proliferate extensively after recognition of HLA-I/viral epitope complex on dendritic cells in the draining lymph nodes and subsequently differentiate into functional effector CTLs. During the convalescent phases following Covid-19, CTLs migrate to extralymphoid tissues, such as lung, to recognise the classical HLA-I/peptide complex on target cells, which in turn exert a potent inhibitory action on viral replication. 24, 25 This step is crucial for clearance and to avoid the virus spreading in tissues. 14, 26 Since HLA-I proteins are essential for T cell stimulation and NK cell modulation, I will address immune evasion mechanisms that target antigen-presentation and NK cell responses.

The classical HLA-I proteins and their associated endogenous route of antigen processing are involved in antiviral CD8 T cell responses during SARS-CoV infection. 27 Given the abilities of SARS-CoV-2 to mutate and increase virion spike density and infectivity, 28 the simplest ways for SARS-CoV-2 to avoid TCD8+ recognition are to mutate their immunoevasin proteins to inhibit HLA-I antigen presentation pathways. Viral proteins produced by this virus such as surface spike (S), nucleocapsid, open reading frame-1ab (ORF1ab), and ORF8 show frequent mutations. 29 The S protein contains neutralisation and CTL epitopes, which are essential to induce adaptive immune responses. It carries spike 1 (SP1) and SP2 domains, 30 which mediate receptor binding and downstream membrane fusion, respectively. 31 In vivo, there is no proof of reduced expression of HLA-A/B/C following infection with SARS-CoV-2. However, in vitro data show that S protein may modulate the expression of HLA-I. 32 When transferred at a higher level (1 μg) to lung epithelial cells, intracellular S protein reduces classical HLA-I (A, B, and C) expression. Indeed, the aberrant expression of HLA-A/B/C was more pronounced when using SP1 than SP2 and S proteins. Whether SP1 affects the expression of other genes involved in the endogenous route of antigen presentation and at which step inhibition occurs in the antigen processing is unknown. Like other human respiratory RNA viruses, 33 variation in the S protein indirectly could potentially manipulate HLA-I antigen presentation pathways by mutating the S protein-specific CTL epitopes binding to HLA-I molecules. 34 However, further experiments will be required to completely understand the effect of three mutations (K417N, E484K and N501Y) 35 in spike on HLA-I antigen presentation pathways. While the immunological effects of the observed decrease are not yet known, I speculate that the loss of HLA-I often leads to a reduction in CTL responses.

A similar function was likely attributed to the ORF8 protein, causing degradation of newly synthesised classical HLA-I molecules in vitro, 36, 37 but these preliminary data warrant confirmation. Deletion in ORF8 (Δ382 variant) was associated with more effective Tcell responses and mild stage of Covid-19, 38 suggesting that the binding of ORF8 protein to HLA-I reduced CTL-mediated antiviral activity. In a preprint study, Weingarten-Gabbay et al. 39 assume that SARS-CoV-2 may interfere with HLA-I antigen presentation pathways through both proteasome maturation protein depletion and by altering ubiquitination enzymes, thereby preventing presentation of highly expressed SARS-CoV-2 proteins by infected cells in vitro. 40 This potential strategy for evasion of production of HLA-I peptides through ubiquitin-proteasome pathway warrants further investigation. In the same way, Middle East respiratory syndrome-coronavirus alters antigen presentation pathways and downregulates classical HLA-I molecules in vitro. 41 

Multiple NK cell receptors (NKRs) govern the NK cell responsiveness capacity through direct or indirect recognition of HLA-I molecules. 41, 42 Such receptors, based on their function, could be subdivided mainly into three groups. NKRs, which utilise classical HLA-I as their ligands, include the killer immunoglobulin-like (KIRs) and human leucocyte immunoglobulin-like (LILRB1 or LIR-1) receptors.

The second subgroup of activating NKp30, 44 and 46 receptors 2 -BOUAYAD recognise virus-derived peptides. 43 The last subgroup includes the NKG2/CD94 complex (NKG2A and NKG2C) and NKG2D. The ligand for NKG2A/C-CD94 is HLA-E. NKG2D does not dimerise with CD94 and recognises at least six ligands (UL16-binding protein, MICA/B, Rae-1, MULT1, H60). 44 The 'missing-self axis' is controlled by inhibitory receptors (NKG2A and KIRs). Whereas KIRs directly scan surface HLA-I molecules, the HLA-E-NKG2A interaction is an indirect immune-surveillance mechanism for the HLA-I expression. 45 Maucourant et al. showed that cytotoxic function of CD56dim NK cells expressing different combinations of inhibitory KIRs and NKG2A in acute Covid-19 occurred independently of inhibitory KIRs expression. Furthermore, another study focussing on circulating NK cells found that only a smaller NK cell subset displayed upregulation of the inhibitory (KIR2DL1 and NKG2A) and activating (KIR2DS1) receptors in patients with ARDS. 46 These data suggest that KIRs do not participate in Covid-19 disease progression. Of note, the presence of other NK receptors such as NKG2A has been correlated with disease severity. 47, 48 The impact of LIR-1 on NK cells' Covid-19 response is more conflicting. There is some evidence that an increase in messenger RNA (mRNA) levels of LIR-1 on monocytes may lead to a mild stage of Covid-19, 49 though it can or cannot reflect increased levels in protein expression. Contrary to this, some studies have failed to replicate these findings and refuted any correlation between LIR-1 and critical Covid-19. 50 It is too early to deduce from a patient that LIR-1 may not affect the severity of Covid-19. 

The overexpression of nonclassical HLA-E is a common observation through a wide range of viral infectious diseases. These molecules have been extensively studied 51 its lower binding affinity to standard HLA-E specific peptides, binds SARS-CoV-2 SP1 derived peptides more efficiently. Therefore, HLA-E may be differentially expressed according to cell types, and thus the effect of SP1 might be cell-type specific. Consequently, HLA-E molecules might exhibit differing affinities with SP1 peptides in a way that correlates with the differing stability and cell surface expression. In agreement, another study suggested that differential S protein stability (and binding to ACE2) may contribute to the varying disease courses. 54 In this study, aa variation in S protein (D614G mutation) correlated with increased viral loads and high transmission but low mortality. Thus, SARS-CoV-2 control appears to have more to do with the status of host defences than the virulence of the virus.

Among genetic factors, polymorphic HLA-E may also be responsible for differential HLA-E expression, and therefore Covid-19 severity.

HLA-E*01:01 allele and heterozygous HLA-E*01:01/03 genotype are associated with severe Covid-19. 55 Thus, the genetic difference at HLA-E alleles may account for individual variations in the NK cell response against SARS-CoV-2 infection.

HLA-E preferentially presents signal peptides derived from other HLA molecules (HLA-A, -B, -C and -G) 56 or from viruses. 57 They also function as ligands for activating or inhibitory receptors, whose 

Overstimulation of NK cells can both increase function and cause exhaustion, often simultaneously. It occurs when activating signals are higher than the inhibiting signals. Many clinical observations suggest that mature NK cells are highly activated after infection with SARS-CoV-2 and participate to worsen lung injury observed in some patients with severe or fatal outcomes. In this context, IgG antibodies is a goal for an effective Covid-19 vaccine, it is becoming clear that IgG that mediates ADCC can provide protective immunity against influenza. 73 Furthermore, important information on immune mechanisms capable of controlling Covid-19 may come from children undergoing an intense immunisation program. 74 The trained immunity elicited by human Bacillus Calmette and Guerin vaccination cannot be excluded to improve this process 75-77 through a more potent cross immune defence in these individuals. Equally important is the question of how the modulation of HLA-I expression by immunoevasins exhausted CTL cytotoxicity, especially in severe cases. As discussed above, there is some evidence NKG2A overexpression on TCD8+ is involved in functional exhaustion of CTLs and disease progression in the early stage of Covid-19. However, the lack of stability of the HLA-E-SP1 complex identified to date limits our ability to study their CTLs responses in detail.

As mentioned previously, one mechanism that SARS-CoV-2 uses to evade adaptive immunity is antigenic variation, in which structural variants emerge that potentially alter HLA-I antigen presentation pathways and enable this virus to persist or infect previously immunised subjects. As a result, it may be challenging to control new strains of SARS-CoV-2 using existing Covid-19 vaccines. Moreover, the complexity of the molecular mechanisms underlying HLA-I alteration expression and other related molecules involved in NK cell recognition makes selecting a therapeutic target to potentiate antiviral immune responses very difficult.

The author thanks Faiza BOUAYAD and Ahmed Amine EL OUMRI for their enormous technical assistance.

The author declares no conflict of interest.

The author confirms sole responsibility for the following: design and writing the manuscript, analysis and discussion of results. The author approved submitted version.

https://orcid.org/0000-0003-4377-0833

Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update

Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions

Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity

Comprehensive mapping of immune perturbations associated with severe COVID-19

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential

SARS-CoV-2 genomic variations associated with mortality rate of COVID-19

The human leucocyte antigen (HLA) system

COVID -19 in older adults: a series of 76 patients aged 85 years and older with COVID-19

Why the elderly appear to be more severely affected by COVID-19: the potential role of immunosenescence and CMV

Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis

Factors associated with death in critically ill patients with coronavirus disease 2019 in the US

Viral escape mechanismsescapology taught by viruses

The MHC class I antigen presentation pathway: strategies for viral immune evasion

Evasion of host immune defenses by human papillomavirus

Angiotensin-converting enzyme 2: the old door for new severe acute respiratory syndrome coronavirus 2 infection

Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

CD94 is essential for NK cell-mediated resistance to a lethal viral disease

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics

Innate immune evasion by SARS-CoV-2: comparison with SARS-CoV

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission

Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-CoV-2 spike 1 protein controls natural killer cell activation via the HLA-E/NKG2A pathway

Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia

CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: implications for disease control and prevention

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK

Immune evasion via SARS-CoV-2 ORF8 protein?

Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-offrame ORFs

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape

Natural killer cell cytotoxicity and its regulation by inhibitory receptors

A bird's eye view of NK cell receptor interactions with their MHC class I ligands

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

NKG2D receptor and its ligands in host defense

Natural killer cell immunotypes related to COVID-19 disease severity

Identification of druggable inhibitory immune checkpoints on natural killer cells in COVID-19

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Immune alterations in a patient with SARS-CoV-2-related acute respiratory distress syndrome

Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection

Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence

bound peptides: recognition by subsets of NK and T cells

Cytomegalovirus-infected primary endothelial cells trigger NKG2C+ natural killer cells

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

The D614G mutations in the SARS-CoV-2 spike protein: implications for viral infectivity, disease severity and vaccine design

Puchhammer-Stöckl E. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19

The HLA system in hematopoietic stem cell transplantation Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation

HLA-E-restricted crossrecognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation

NKG2A and COVID-19: another brick in the wall

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Predictive nomogram for severe COVID-19 and identification of mortality-related immune features

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells

A conserved HIV-1-derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A/CD94-bearing natural killer cells

The human major histocompatibility complex: lessons from the DNA sequence

Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Unique immunological profile in patients with COVID-19

The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system

Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma

Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment

Antibody status and incidence of SARS-CoV-2 infection in health care workers

Antibodydependent cellular cytotoxicity and influenza virus

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents

SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics

BCG-induced trained immunity in NK cells: role for non-specific protection to infection

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

How to cite this article: Bouayad A. Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far